Neutralization of Variant Under Investigation B.1.617.1 With Sera of BBV152 Vaccinees
Top Cited Papers
- 7 May 2021
- journal article
- letter
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 74 (2), 366-368
- https://doi.org/10.1093/cid/ciab411
Abstract
Pragya D Yadav, Ph.D, Gajanan N Sapkal, Ph.D, Priya Abraham, M.D, Ph.D, Raches Ella, M.S, Gururaj Deshpande, Ph.D, Deepak Y Patil, Ph.D, Dimpal A Nyayanit, Ph.DThis publication has 8 references indexed in Scilit:
- Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBV152: a double-blind, randomised, phase 1 trialThe Lancet Infectious Diseases, 2021
- Neutralizing Activity of BNT162b2-Elicited SerumThe New England Journal of Medicine, 2021
- Inactivated COVID-19 vaccine BBV152/COVAXIN effectively neutralizes recently emerged B.1.1.7 variant of SARS-CoV-2Journal of Travel Medicine, 2021
- Isolation and characterization of the new SARS-CoV-2 variant in travellers from the United Kingdom to India: VUI-202012/01 of the B.1.1.7 lineageJournal of Travel Medicine, 2021
- A dynamic nomenclature proposal for SARS-CoV-2 lineages to assist genomic epidemiologyNature Microbiology, 2020
- Neutralizing antibody responses to SARS-CoV-2 in COVID-19 patientsIndian Journal of Medical Research, 2020
- First isolation of SARS-CoV-2 from clinical samples in IndiaIndian Journal of Medical Research, 2020
- Complete genome sequencing of Kaisodi virus isolated from ticks in India belonging to Phlebovirus genus, family PhenuiviridaeTicks and Tick-borne Diseases, 2018